85 related articles for article (PubMed ID: 23346639)
1. [Aprepitant and pruritus--comment].
Manasek V
Klin Onkol; 2012; 25(6):491-2. PubMed ID: 23346639
[No Abstract] [Full Text] [Related]
2. Topical aprepitant in clinical and experimental pruritus.
Wallengren J
Arch Dermatol; 2012 Aug; 148(8):957-9. PubMed ID: 22911202
[No Abstract] [Full Text] [Related]
3. Aprepitant against pruritus in patients with solid tumours.
Vincenzi B; Fratto ME; Santini D; Tonini G
Support Care Cancer; 2010 Sep; 18(9):1229-30. PubMed ID: 20544226
[No Abstract] [Full Text] [Related]
4. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
5. Aprepitant as an antipruritic agent?
Duval A; Dubertret L
N Engl J Med; 2009 Oct; 361(14):1415-6. PubMed ID: 19797294
[No Abstract] [Full Text] [Related]
6. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
Nieber K; Schoppmeyer K
Pharm Unserer Zeit; 2007; 36(5):373-80. PubMed ID: 17722144
[No Abstract] [Full Text] [Related]
9. Aprepitant for pruritus: drug-drug interactions matter.
Mir O; Coriat R
Lancet Oncol; 2012 Oct; 13(10):964-5. PubMed ID: 22995652
[No Abstract] [Full Text] [Related]
10. Aprepitant for erlotinib-induced pruritus.
Vincenzi B; Tonini G; Santini D
N Engl J Med; 2010 Jul; 363(4):397-8. PubMed ID: 20660413
[No Abstract] [Full Text] [Related]
11. Aprepitant for erlotinib-induced pruritus.
Levêque D
N Engl J Med; 2010 Oct; 363(17):1680-1; author reply 1681. PubMed ID: 20961258
[No Abstract] [Full Text] [Related]
12. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
13. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
14. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
16. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Viale PH
Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
Smith AR; Repka TL; Weigel BJ
Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
Osorio-Sanchez JA; Karapetis C; Koczwara B
Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
